Evotec SE (EVO) Cash from Investing Activities Growth (1y) (2010 - 2026)
Evotec SE (EVO) Cash from Investing Activities Growth (1y) (2010 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 13.93% |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | 57.14% |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | -186.78% |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 551.55% |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 526.11% |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | -3,664.79% |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | -3.45% |
| 10 | Evotec SE | 339.17 Mn | 338.65 Mn | - | 35.95% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 35.95% |
| Dec 31, 2025 | 362.98% |
| Sep 30, 2025 | 70.26% |
| Jun 30, 2025 | 26.27% |
| Mar 31, 2025 | 32.31% |
| Dec 31, 2024 | -430.62% |
| Sep 30, 2024 | -116.42% |
| Jun 30, 2024 | -228.16% |
| Mar 31, 2024 | -772.15% |
| Dec 31, 2023 | 96.60% |
| Sep 30, 2023 | 94.28% |
| Jun 30, 2023 | 122.17% |
| Mar 31, 2023 | 104.65% |
| Dec 31, 2022 | -51.38% |
| Sep 30, 2022 | -487.98% |
| Jun 30, 2022 | -202.03% |
| Mar 31, 2022 | -191,439.37% |
| Jun 30, 2010 | 20.31% |
| Mar 31, 2010 | -256.04% |